Recent advances in colony stimulating factor-1 receptor (CSF1R) inhibitors

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Colony-stimulating factor-1 receptor (CSF1R), a type III receptor tyrosine kinase, regulates mononuclear phagocyte populations, including microglia.
• Aberrant CSF1R expression is linked to tumors and neurodegenerative diseases.
• CSF1R signaling pathways are crucial for cell survival, proliferation, and differentiation.

Purpose of the Study:

• To review recent advancements in CSF1R inhibitors for clinical applications.
• To focus on therapeutic progress in oncology and neurological disorders.
• To discuss inhibitor binding modes, selectivity, CNS penetration, and toxicity.

Main Methods:

• Literature review of recent studies on CSF1R inhibitors.
• Analysis of clinical applications and disease models.
• Examination of targeted delivery systems and inhibitor properties.

Main Results:

• CSF1R inhibitors offer a promising strategy for cancer therapy by modulating the tumor microenvironment.
• Targeting CSF1R is beneficial for neurodegenerative and neuroinflammatory conditions.
• Advances in inhibitor design aim to enhance selectivity and CNS penetration while reducing toxicity.

Conclusions:

• CSF1R inhibitors represent a significant therapeutic avenue for both oncology and neurology.
• Further research into targeted delivery and inhibitor optimization is crucial for clinical success.
• Modulating CSF1R signaling holds potential for treating a range of diseases with unmet needs.